Zur Zeit eine ganz heisse Pille!
Seite 1 von 2 Neuester Beitrag: 24.09.14 09:18 | ||||
Eröffnet am: | 09.09.02 20:07 | von: Gruenspan | Anzahl Beiträge: | 35 |
Neuester Beitrag: | 24.09.14 09:18 | von: Andrew6466 | Leser gesamt: | 42.758 |
Forum: | Börse | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < | 2 > |
Es gab positive News, welche sich not bad auf die akt. Kursentwicklung auswirken.
Wenn, dann in USA ordern, oder ordern lassen.
Dort gehen reichlich Stücke um, hier leider nicht.
Gib mal ITMN in die Suchleiste ein.
;-)
Jetzt geht wieder was.
Watt sachste jetzt dazu?
;-)))
Gr.Gr.
Datt tut dem gruenen Depot richtig gut.
;-)
PS: Wer aufgrund der Performance bei Intermune jetzt Muffe hat, aber auch noch auf Pharma setzen möchte, sollte sich mal eine andere Pille anschauen.
Nämlich Ashland Inc. (ASH) (NYSE) oder WKN: 853971!
Die schauen genau wie ITMN einem Rebound entgegen.
Jedenfalls kündigt der Chart auch bei ASH selbiges an.
Also, US- Fans, würde ich mir mal näher anschauen.
;-)))
Es müssen nicht immer Cisco, Intel oder Oracle und Co sein, die dem Anleger Freude machen;-)
Auch die kleinen feinen Werte, sollte man nicht verachten.
Und Stücke, da gehen in New York immer reichlich davon um.
Gr.Gr.
Kennst Du Taro Pharmaceuticals auch, downgrades gabs bei 22 Dollar, dann gings
hoch.
Shares of Amylin (AMLN: news, chart, profile) climbed $1.50 to $13.90. Shares of Eli Lilly (LLY: news, chart, profile) tacked on $1.01 to $56.33.
NEWS FOR AMLN
Amylin shares propelled by Lilly diabetes deal
Amylin jumps, biotech sector mixed
More news for AMLN
Company: Amylin Pharmaceuticals Inc Add
Create
Column: Biotech Report
Create
Company: Eli Lilly and Company Add
Create
Create A Portfolio | Create An Alert
Eli Lilly and Amylin said they agreed to a partnership to develop and market Amylin's experimental treatment for type 2 diabetes, the most prevalent form of the disease. The drug, called AC2993, is now in late-stage patient testing.
Under terms of the deal, Lilly said it'll make initial, nonrefundable payments to Amylin totaling $80 million.
Lilly will also purchase $30 million of Amylin stock at $18.69 per share. In addition, in the future, Lilly said it'll pay Amylin up to $85 million provided certain development and product milestones are met.
Lilly will also make additional future payments to Amylin of up to $130 million contingent on global commercialization of AC2993, including long-acting release formulations of the product candidate.
Lilly further agreed to share in development and marketing costs for the diabetes drug.
Provided certain goals are met, including successful completion of the late-stage tests, Lilly said it'll make a $110 million convertible loan to San Diego-based Amylin.
In return, Lilly gets a big share of future profits, presuming the drug makes it to market. The companies will share equally in any U.S. profits and outside of the United States Lilly gets 80 percent of profits.
There's no guarantee, however, that the experimental compound will ever make it to market. The outcome of the ongoing tests will be crucial in determining the drug's fate. The companies said 2004 is the earliest they could apply for U.S. regulatory clearance to market the drug.
Diabetes is among the leading killers in the industrialized world. It occurs when a person's body either stops making, or develops resistance to, the hormone insulin, which is essential for controlling blood sugar levels.
In the United States, 17 million people have diabetes, 90 percent of whom have the type 2 form, according to estimates cited by the companies.
Ted Griffith is a reporter for CBS.MarketWatch
InterMune, Array BioPharma In Drug Discovery Collaboration
Updated: Monday, September 30, 2002 09:54 AM ET Printer-friendly version
BRISBANE, Calif. -(Dow Jones)- InterMune Inc. (ITMN, news) and Array BioPharma Inc. (ARRY, news) agreed to cooperate in developing small-molecule therapeutics for hepatitis.
In a press release Monday, the companies said InterMune will fund drug discovery research conducted by Array and will be responsible for all development and commercialization.
Array, Boulder, Colo., will be entitled to receive undisclosed development milestone payments and royalties on product sales. Other terms weren't disclosed.
InterMune, Brisbane, Calif., develops therapies for pulmonary disease, infectious disease and cancer.
Company Web sites: www.intermune.com www.arraybiopharma.com
Forest Laboratories Will Exceed Estimates for Fiscal 2003
Second Quarter Sales and Earnings
MONDAY, SEPTEMBER 30, 2002 4:05 PM
- PR Newswire
NEW YORK, Sep 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- Forest
Laboratories, Inc. (FRX) today announced that it expects its fiscal 2003 second
quarter performance to exceed current consensus estimates. The Company
projects that earnings per share will exceed the current First Call consensus
estimate of $0.57 per share by at least 30%. In the second quarter of last fiscal
year Forest earned $0.43 per share.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
The Company indicated that the primary reason for the better than anticipated
performance in the quarter is strong net sales volume which will be approximately
$530 million. Sales during the quarter were primarily driven by the Company's
antidepressant franchise. The Company projects that sales of its antidepressant
Celexa(TM) should approximate $388 million in the quarter. Sales of its
antidepressant Lexapro(TM), introduced in September, should approximate $22
million in the quarter which includes initial wholesaler stocking of the product. The
Company is not aware of any changes in inventory levels for its products at
pharmaceutical wholesalers or distributors.
Selling, general and administrative expenses for the quarter will be approximately
$180 million as compared to $155 million in the Company's first quarter. SG&A
expenses in the second quarter reflect the early investment associated with the
launch of Lexapro, however, given the product's launch late in the quarter the full
impact of Lexapro launch expenses will not be realized until the Company's quarter
ending December 31, 2002.
Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories,
commented: "The strong performance of our business this quarter has resulted in
financial performance above consensus expectations. Our antidepressant franchise
continues to gain share in a large and growing market and, although early in the
launch cycle, we have been encouraged by the performance of Lexapro. We will
continue to assess factors associated with our business for the remainder of the
fiscal year and be in a position to offer financial guidance for the fiscal year ending
March 31, 2003 in connection with our second quarter earnings release."
Forest plans to issue its second quarter fiscal 2003 earnings on October 15, 2002
and will hold an investor conference call to discuss the results.
Aber Geschmackssache.
07.10.2002
King Pharmaceutical "buy"
Punk Ziegel & Co.
Rating-Update:
Die Analysten vom Investmenthaus Punk Ziegel & Co stufen die Aktie von King Pharmaceuticals (WKN 911091) in einer Ersteinschätzung mit "buy" ein. Das Kursziel sehe man bei 30,25 US-Dollar.
Für 16 Dollar ein Super-Schnäppchen sage ich Dir, steig mal jetzt getrost ein.
Gewinne mehr als sicher.
Gr. E.
Mit einem Anti-Depressivum, speziell dosiert und zusammengesetzt für Aktionäre, könnte man sich heutzutage wahrscheinlich dumm und dusselig verdienen !
Forest Labs' fiscal second-quarter net income soared nearly 80 percent, driven by strong sales of antidepressants, the drugmaker reported Tuesday. Forest said net income climbed to $142.8 million, or 77 cents per share, from $80 million, or 43 cents per share, in the year-ago period. New York-based Forest had been expected to earn 74 cents per share, according to the average estimate of analysts polled by Thomson First Call. Second-quarter sales rose 41 percent to $531.6 million with antidepressants Celexa and Lexapro accounting for much of the increase. Ahead of the news, shares of Forest (FRX) closed up $1.27 to $93.50 on Monday.
Total solide 40% Chance. Kurs derzeit 17,50, Kursziel mindestens 25 Dollar bis
März 2003. Für alle die es konservativ mögen und ein bisschen warten können.
Gruss E.
King Pharma earns grow, top expectations (7:40 AM ET) King Pharmaceuticals(KG: news, chart, profile)reported third-quarter earnings that rose over year-earlier levels and topped Wall Street expectations and said it remained "comfortable" with current earnings projections for the fourth quarter and for 2003. Net earnings for the quarter ending September, excluding non-recurring items, were $84.7 million, or 35 cents a share, up from last year's 28 cents a share. Total revenue rose 37 percent to $315.7 million. Analysts surveyed by Thomson First Call had been expecting earnings of 34 cents a share and revenue of $306.8 million, on average. The branded drug maker's stock closed Friday down 69 cents at $17.
Da hab ich wohl bei 35$ etwas zu zeitig verkauft:-(
der die DAX-Pleite von Juni-September voll nachvollzogen hat, mit seinem ihm anvertrauten Vermögen. Wütende Kunden
haben ihn einen "übergelatzt" und er fühlt sich persönlich
getroffen, obwohl er 30 Jahre Börsenerfahrung hat und eine
"eigenständige" Volkswirtschaftliche Analyse erstellen kann.
Zum Glück sieht man mal wieder, dass das an der Börse natür-
lich alles nichts nützt.
Seine Depotpositionen im Schnitt 50% im Minus. Glückwunsch.
Gruss E.
Die Übernahme von MTEC ist verdaut, die Zahlen und Aussichten waren glänzend.
Wenn nächste Woche die 19 Dollar geknackt werden, gehts auch mindestens bis zu den prognostizierten 25 Dollar hoch.
Gruss E.
1:47PM Forest Labs breaks out to new 52-wk high (FRX) 55.41 +1.16: Shares of the branded and generic drug company are clearing their former one-yr high of $54.99 set Dec. 2.
--------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Der Medikamentenhersteller King Pharmaceuticals (WKN: 911091, US: KG) teilt am Dienstag mit, dass die US-Börsenaufsichtsbehörde SEC eine Ermittlung im Unternehmen wegen möglicher Schwindeleien bei der Verbuchung von Umsätzen initiiert habe. Das Unternehmen habe eine Vorladung und eine briefliche Benachrichtigung von der SEC erhalten, hieß es. Die Anfrage beziehe sich auf die Preisfestsetzung innerhalb des Medicaid-Programmes im Jahr 1999, auf Verkäufe an die beiden Unternehmen VitaRx und Prison Health Services sowie auf Rabatte, die auf das Bluthochdruckmedikament Altace vergeben wurden.
Grüße Pavian